Anal fistula medical therapy

Jump to navigation Jump to search

Anal fistula Microchapters


Patient Information


Historical Perspective




Differentiating Anal fistula from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Diagnostic study of choice

Laboratory Findings

X Ray





Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Anal fistula medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Anal fistula medical therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Anal fistula medical therapy

CDC on Anal fistula medical therapy

Anal fistula medical therapy in the news

Blogs on Anal fistula medical therapy

Directions to Hospitals Treating Anal fistula

Risk calculators and risk factors for Anal fistula medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]


Pharmacotherapy used in anal fistula depends upon the location and symptoms of patient. Antibiotics are used in patient with comorbities like immunosuppression, diabetes, extensive cellulitis, prosthetic devices and high risk cardiac patients. Antipyretics and analgesic for symptomatic relief of pain and fever. Treatment of underlying causes is important to treat recurrent anal fistulas.


Treatment of underlying cause


  1. "" (PDF).
  2. Whiteford MH, Kilkenny J, Hyman N, Buie WD, Cohen J, Orsay C, Dunn G, Perry WB, Ellis CN, Rakinic J, Gregorcyk S, Shellito P, Nelson R, Tjandra JJ, Newstead G (2005). "Practice parameters for the treatment of perianal abscess and fistula-in-ano (revised)". Dis. Colon Rectum. 48 (7): 1337–42. doi:10.1007/s10350-005-0055-3. PMID 15933794.
  3. Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P, Gewitz MH, Shulman ST, Nouri S, Newburger JW, Hutto C, Pallasch TJ, Gage TW, Levison ME, Peter G, Zuccaro G (1997). "Prevention of bacterial endocarditis. Recommendations by the American Heart Association". Circulation. 96 (1): 358–66. PMID 9236458.
  4. Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ (2006). "Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study". Aliment. Pharmacol. Ther. 23 (8): 1127–36. doi:10.1111/j.1365-2036.2006.02878.x. PMID 16611273.
  5. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ (2004). "Infliximab maintenance therapy for fistulizing Crohn's disease". N. Engl. J. Med. 350 (9): 876–85. doi:10.1056/NEJMoa030815. PMID 14985485.
  6. Taxonera C, Schwartz DA, García-Olmo D (2009). "Emerging treatments for complex perianal fistula in Crohn's disease". World J. Gastroenterol. 15 (34): 4263–72. PMC 2744181. PMID 19750568.
  7. Bokhari I, Shah SS, Inamullah, Mehmood Z, Ali SU, Khan A (2008). "Tubercular fistula-in-ano". J Coll Physicians Surg Pak. 18 (7): 401–3. doi:06.2008/JCPSP.401403 Check |doi= value (help). PMID 18760061.
  8. Donoghue HD, Holton J (2009). "Intestinal tuberculosis". Curr. Opin. Infect. Dis. 22 (5): 490–6. doi:10.1097/QCO.0b013e3283306712. PMID 19623062.

Template:WH Template:WS